Current Status of India’s Healthcare, Biopharma Sector
- Global Exports: India exports medical devices to 187 countries (FY25), signalling rising global competitiveness.
- Generic Leadership: The pharma sector supplies ~20% of global generic medicines, ranking 3rd by volume worldwide, earning the tag “Pharmacy of the World.”
- Biotech Scale: India’s bioeconomy has grown from $10 billion in 2014 to $165.7 billion in 2024, with a target of $300 billion by 2030.
- Export Growth: Medical device exports increased from USD 2.5 bn (FY21) to USD 4.1 bn (FY25), showing rapid sectoral expansion.
- Healthcare Growth: India’s healthcare market is projected to reach US$320 billion by 2028, driven by hospitals, diagnostics and medical tourism.
Healthcare and Pharma Announcements in Union Budget 2026-27
- Medical Hubs: The government will establish five Regional Medical Hubs under a Public-Private Partnership (PPP) model to integrate allopathic and traditional medicine.
- Biopharma Mission: A new scheme titled ‘Biopharma SHAKTI’ is launched with an outlay of ₹10,000 crore to boost domestic production of biologics and biosimilars.
- Infrastructure Expansion: Three new All India Institute of Ayurveda will be set up, along with the upgradation of Ayush pharmacies and drug testing labs.
- Research Network: A network of over 1,000 accredited clinical trial sites will be created to make India a preferred global destination for drug research.
- Regulatory Reform: The CDSCO will be strengthened with a dedicated scientific review cadre to align Indian approval timelines with global standards.
- Skill Development: Three new National Institutes of Pharmaceutical Education and Research (NIPERs) will be established to create a high-skilled workforce for the biopharma sector.
Strategic Impact of the Measures
- Value Shift: The focus on ‘Biopharma SHAKTI’ marks a strategic shift from low-cost generic drug manufacturing to high-value complex biologics and innovation.
- Brand Differentiation: Integrating Ayush centres into Regional Medical Hubs creates a unique “Holistic Health” brand that combines modern surgery with traditional wellness.
- Employment Generation: The establishment of integrated healthcare hubs will create high-quality jobs for doctors, nurses, researchers, and allied health professionals.
- Import Reduction: Domestic manufacturing of biosimilars will significantly reduce India’s reliance on costly imports for critical therapies like cancer treatment.
- Global Credibility: The accreditation of 1,000+ clinical trial sites addresses global concerns about data integrity and reliability in Indian clinical trials.
- Agrarian Boost: The promotion of Ayurveda exports directly benefits farmers cultivating medicinal herbs and plants.
Government-Led Healthcare & Pharma Initiatives
- Heal in India: A flagship initiative offering a digital portal to assist international patients with visa facilitation and hospital selection.
- Heal by India: Designed to train Indian healthcare professionals (doctors and nurses) to meet global workforce demands.
- PLI Scheme for Pharmaceuticals: A Production Linked Incentive scheme aims to reduce import dependence on Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs).
- E-Medical Visa: The government has expanded the e-medical visa facility to 160+ countries, allowing triple entry and longer stays for treatment.
- Ayush Mark: A quality certification scheme was launched to authenticate and standardise Ayush products for the domestic and global market.
- Bulk Drug Parks: Three mega bulk drug parks are being developed in Gujarat, Himachal Pradesh, and Andhra Pradesh to reduce manufacturing costs through common infrastructure.
- BioE3 Policy: The policy focuses on “Biotechnology for Economy, Environment and Employment” to foster high-performance biomanufacturing.
Structural Challenges to Address
- Regulatory Vacuum: The medical tourism sector lacks a centralised regulator to standardise treatment rates and prevent malpractice against foreign patients.
- Data Gaps: There is no comprehensive national database to track the inflow of medical tourists, their preferred procedures, or their countries of origin.
- Quality Concerns: Recent global alerts about Indian cough syrups and vaccines underscore the urgent need to overhaul drug-testing systems beyond infrastructure upgrades.
- Investment Deficit: India’s R&D spending in the pharmaceutical sector remains significantly lower (~8% of sales) than that of global giants (~20% of sales).
- Accreditation Gap: The country has fewer JCI (Joint Commission International)-accredited hospitals than competitors like Thailand, undermining trust among Western patients.
Way Forward
- Regulatory Reform: Create a central medical tourism authority, like Thailand’s model, to standardise costs and ensure patient safety.
- R&D Boost: Raise pharma R&D from ~8% to global ~20% of sales, supported by Biopharma SHAKTI.
- Accreditation Drive: Expand JCI/NABH accreditation; India currently lags behind Thailand’s ~80 JCI hospitals.
- Data Integration: Build a national database to track ~10 lakh foreign patients, their treatments, and origin countries.
- Skill & Infrastructure: Strengthen 5 PPP-based Regional Medical Hubs, over 1,000 clinical trial sites, and National Institute of Pharmaceutical Education and Research (NIPERs) for a skilled workforce.
“From cost to credibility.” With regulatory rigour, innovation-led biomanufacturing and Ayush integration, India can emerge as a trusted global healthcare and biopharma hub by 2047.
Reference: The Indian Express | PMFIAS: India’s Hospital Industry
PMF IAS Pathfinder for Mains – Question 533
Q. Union Budget 2026-27 marks a strategic shift towards positioning India as a global hub for medical tourism and biopharmaceutical innovation. Examine the strategic significance of these measures and assess the challenges in translating intent into global credibility. (250 Words) (15 Marks)
Approach
- Introduction: Write a brief introduction about the medical tourism and biopharmaceutical sector.
- Body: Write the strategic significance of measures of the Union Budget 2026-27, assess the challenges, and the way forward.
- Conclusion: Emphasis on an integrated and coordinated approach to emerge India as a trusted global healthcare and biopharma hub by 2047.
